Why the study?
Do patients with a history of acute myocardial infarction or primary hypertension have an increased incidence of activated protein C resistance and the factor V Leiden mutation compared to controls?
Do patients with a history of acute myocardial infarction or primary hypertension have an increased incidence of activated protein C resistance and the factor V Leiden mutation compared to controls?
Patients with a history of acute myocardial infarction or primary hypertension have a significantly higher prevalence of activated protein C resistance and the factor V Leiden mutation, suggesting these anticoagulant defects may be risk factors for arterial thrombosis.
Answers are grounded in this paper and cite their sources.
APC-R and FV Q506 mutation were associated with AMI and PH; hypothesis-generating for arterial thrombosis risk, should not change practice.
This study was designed to investigate both resistance to activated protein C (APC-R) and the factor FV Q506 mutation incidence in patients with a history of acute myocardial infarction (AMI) and patients with primary hypertension (PH), a high-risk group for arterial thrombosis. Eighty patients with a history of AMI (group A), 160 patients with a history of PH (group B), and 124 age-matched controls without arterial disease (group C) were studied. APC-R was determined using the Coatest APC Resistance Kit of Chromagenix, Sweden. The prevalence of the FV Q506 mutation was estimated by DNA analysis (Bertina method). The prevalence of the FV Q506 mutation was 20%, 13.75%, and 8% in groups A, B, and C, respectively (A v C P = .0466). The prevalence of APC-R was 47.5% in group A v 13% in group C (P < .0001) and 36.25% in group B v 13% in group C (P < .0001). The response to activated protein C expressed as mean value +/- SD was 2.05 +/- 0.33 in group A v 2.56 +/- 0.46 in group C (P < .05) and 2 +/- 0.22 in group B v 2.56 +/- 0.46 in group C (P < .05). These findings suggest that patients with a history of AMI or PH have a significantly increased incidence of both APC-R and FV Q506 mutation compared with the control group. These findings support the hypothesis that these anticoagulant defects may be risk factors for arterial thrombosis.
No takes yet. Share an insight, caveat, or question.
T. Makris (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: